Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
Operating Income
Ocular Therapeutix Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Operating Income
-$91.4m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$24.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$10.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$11.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
See Also
What is Ocular Therapeutix Inc's Operating Income?
Operating Income
-91.4m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Operating Income amounts to -91.4m USD.
What is Ocular Therapeutix Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-19%
Over the last year, the Operating Income growth was -10%. The average annual Operating Income growth rates for Ocular Therapeutix Inc have been -11% over the past three years , -7% over the past five years , and -19% over the past ten years .